(Q40507551)

21 September 2017

A recombinant envelope protein vaccine against West Nile virus (English)

1 reference

21 September 2017

0 references

1

Michel Ledizet

0 references

Erol Fikrig

7

object named as

Erol Fikrig

1 reference

21 September 2017

4

Tian Wang

1 reference

21 September 2017

6

John F Anderson

1 reference

21 September 2017

Kalipada Kar

2

1 reference

21 September 2017

Harald G Foellmer

3

1 reference

21 September 2017

Sandra L Bushmich

5

1 reference

21 September 2017

Raymond A Koski

8

1 reference

21 September 2017

language of work or name

English

0 references

publication date

6 April 2005

1 reference

21 September 2017

1 reference

21 September 2017

23

1 reference

21 September 2017

30

1 reference

21 September 2017

3915-3924

1 reference

The molecular biology of West Nile Virus: a new invader of the western hemisphere

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

West Nile virus: a growing concern?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

West Nile virus: a primer for the clinician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

7 January 2021

West Nile encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Investigation of an outbreak of encephalomyelitis caused by West Nile virus in 136 horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Human immunoglobulin as a treatment for West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Yellow fever vector live-virus vaccines: West Nile virus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

A live attenuated West Nile virus strain as a potential veterinary vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

7 January 2021

West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Immunization with Heterologous Flaviviruses Protective Against Fatal West Nile Encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Mimicking live flavivirus immunization with a noninfectious RNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Recent advancement in flavivirus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Immunization of mice against West Nile virus with recombinant envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Isolation of West Nile virus from mosquitoes, crows, and a Cooper's hawk in Connecticut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

A phylogenetic approach to following West Nile virus in Connecticut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Immunoassay Targeting Nonstructural Protein 5 To Differentiate West Nile Virus Infection from Dengue and St. Louis Encephalitis Virus Infections and from Flavivirus Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Detection of human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere immunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Structure of West Nile Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Live flavivirus vaccines: reasons for caution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Humoral response to West Nile virus vaccination in alpacas and llamas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Experimental infection of horses with West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Transmission of West Nile Virus through Blood Transfusion in the United States in 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.006

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.03.006

1 reference

21 September 2017

1 reference